|Status: One Wales interim decision|
Using the agreed starting and stopping criteria, rituximab can be made available within NHS Wales:
Rituximab should be prescribed on the basis of lowest acquisition cost.
The risks and benefits of the off-label use of rituximab for these indications should be clearly stated and discussed with the patient to allow informed consent.
Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.
This advice will be reviewed after 12 months or earlier if new evidence becomes available.
|Formulation||Concentrate for solution for infusion|
For the treatment of generalised myasthenia gravis in adults.
|BNF chapter||Musculoskeletal & joint diseases|
|Submission type||One Wales|
|Status||One Wales interim decision|
|AWMSG meeting date||19/04/2023|
|Ratification by Welsh Government||25/04/2023|
|Date of issue||26/04/2023|